

Amendments to the Claims

Please cancel Claims 2, 6 and 13.

Please amend Claims 1, 3-5, 7-8, 11-12, and 14-15.

Please add new Claims 16-25.

The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1. (Currently Amended) A method of treating TNF α -mediated hepatitis pathologies involving TNF in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF α -inhibiting amount of an ~~anti-TNF~~ anti-TNF α chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF α chimeric antibody competitively inhibits binding of ~~TNF~~ human TNF α to anti-TNF α chimeric monoclonal antibody cA2.
2. (Canceled)
3. (Currently Amended) A method of treating TNF α -mediated hepatitis pathologies involving TNF in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF α -inhibiting amount of ~~chimeric anti-TNF~~ anti-TNF α chimeric monoclonal antibody cA2.
4. (Currently Amended) A method for treating TNF α -mediated hepatitis pathologies involving TNF in a human comprising administering to the human at least one anti-TNF α chimeric monoclonal antibody cA2, or an antigen-binding a-TNF binding fragment thereof.
5. (Currently Amended) A method of treating TNF α -mediated hepatitis pathologies involving TNF in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF α -inhibiting amount of an ~~anti-TNF~~ anti-TNF α chimeric

antibody, wherein said ~~anti-TNF~~ anti-TNF α chimeric antibody comprises an IgG1 constant region and competitively inhibits binding of ~~TNF~~ human TNF α to ~~anti-TNF α chimeric~~ monoclonal antibody cA2.

6. (Canceled)
7. (Currently Amended) A method of treating TNF α -mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF α -inhibiting amount of an ~~anti-TNF~~ anti-TNF α chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF α chimeric antibody comprises a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
8. (Currently Amended) A method of treating TNF α -mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ TNF α -inhibiting amount of an ~~anti-TNF~~ anti-TNF α chimeric antibody, wherein said ~~anti-TNF~~ anti-TNF α chimeric antibody comprises an IgG1 human constant region and a non-human variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO.:3 and SEQ ID NO.:5.
9. (Original) The method of Claim 7 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.:4.
10. (Original) The method of Claim 8 wherein the non-human variable region comprises a polypeptide encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO.:2 and SEQ ID NO.: 4.

11. (Currently Amended) A method of treating ~~inflammation associated with $TNF\alpha$ -mediated~~ hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ $TNF\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti- $TNF\alpha$ chimeric antibody, wherein said ~~anti-TNF~~ anti- $TNF\alpha$ chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.
12. (Currently Amended) A method of treating inflammation associated with $TNF\alpha$ -mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ $TNF\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti- $TNF\alpha$ chimeric antibody, wherein said ~~anti-TNF~~ anti- $TNF\alpha$ chimeric antibody competitively inhibits binding of ~~TNF~~ human $TNF\alpha$ to anti- $TNF\alpha$ chimeric monoclonal antibody cA2.
13. (Canceled)
14. (Currently Amended) A method of treating inflammation associated with $TNF\alpha$ -mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ $TNF\alpha$ -inhibiting amount of ~~chimeric anti-TNF~~ anti- $TNF\alpha$ chimeric monoclonal antibody cA2.
15. (Currently Amended) A method of treating inflammation associated with $TNF\alpha$ -mediated hepatitis ~~pathologies involving TNF~~ in a human comprising administering to the human an effective ~~TNF-inhibiting~~ $TNF\alpha$ -inhibiting amount of an ~~anti-TNF~~ anti- $TNF\alpha$ chimeric antibody, wherein said ~~anti-TNF~~ anti- $TNF\alpha$ chimeric antibody has epitopic specificity identical to monoclonal antibody cA2.
16. (New) The method of Claim 1 wherein said chimeric anti- $TNF\alpha$ antibody binds to a neutralizing epitope of human $TNF\alpha$.

17. (New) A method of treating TNF α -mediated hepatitis in a human comprising administering to the human an effective TNF α -inhibiting amount of an anti-TNF α antibody, wherein said anti-TNF α antibody competitively inhibits binding of human TNF α to anti-TNF α chimeric monoclonal antibody cA2.
18. (New) The method of Claim 1 wherein said anti-TNF α antibody binds with high affinity to a neutralizing epitope of human TNF α .
19. (New) The method of Claim 1 wherein said anti-TNF α antibody binds to a neutralizing epitope of human TNF α *in vivo* with an affinity of at least 1×10^8 liter/mole, measured as an association constant (K_a), as determined by Scatchard analysis.
20. (New) The method of Claim 1 wherein said anti-TNF α antibody is administered to the human by means of parenteral administration.
21. (New) The method of Claim 1 wherein said anti-TNF α antibody is administered to the human by means of intravenous administration, subcutaneous administration or intramuscular administration.
22. (New) The method of Claim 1 wherein said anti-TNF α antibody is administered to the human orally.
23. (New) The method of Claim 1 wherein said TNF α -inhibiting amount of the anti-TNF α antibody comprises a single or divided dose of about 0.1 - 50 mg/kg.
24. (New) The method of Claim 23 wherein said single or divided dose is selected from the group consisting of: about a 0.1 - 1 mg/kg dose, about a 1.0 - 5 mg/kg dose, about a 5 - 10 mg/kg dose and about a 10 - 20 mg/kg dose.

25. (New) The method of Claim 1 further comprising administering to the human an effective amount of a therapeutic agent selected from the group consisting of: radiotherapeutics, cytotoxic drugs, monoclonal antibodies, chimeric antibodies, antibody fragments, antibody regions, lymphokines, cytokines, hemopoietic growth factors and immunoglobulins.